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Abstract
Background: Within a population, the differences of pharmacogenomic variant frequencies may produce diversities
in drug efficacy, safety, and the risk associated with adverse drug reactions. With the development of
pharmacogenomics, widespread genetic research on drug metabolism has been conducted on major populations,
but less is known about minorities.
Results: In this study, we recruited 100 unrelated, healthy Mongol adults from Xinjiang and genotyped 85 VIP
variants from the PharmGKB database. We compared our data with eleven populations listed in 1000 genomes
project and HapMap database. We used χ2 tests to identify significantly different loci between these populations.
We downloaded SNP allele frequencies from the ALlele FREquency Database to observe the global genetic
variation distribution for these specific loci. And then we used Structure software to perform the genetic structure
analysis of 12 populations.
Conclusions: Our results demonstrated that different polymorphic allele frequencies exist between different
nationalities,and indicated Mongol is most similar to Chinese populations, followed by JPT. This information on the
Mongol population complements the existing pharmacogenomic data and provides a theoretical basis for
screening and therapy in the different ethnic groups within Xinjiang.
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Background
It is well known that different individuals have different
reactions to the same medications. Pharmacogenomics
seeks to identify genetic markers that may influence a
person’s response to pharmaceuticals. It will undoubt-
edly become an indispensable part of medical care in the
future [1, 2]. Pharmacogenomic research seeks to iden-
tify single nucleotide polymorphisms (SNPs) or multiple
gene signatures that are possibly associated with medica-
tion responses [3]. The goal of the research is to provide
information for personalized medicine, i.e. give to the
patient the optimal medication in optimal dose, and pro-
mote personalized therapeutics [4–6].
Numerous studies had shown that certain important
genes and genetic variations affect critical functions dur-
ing the drug reaction process. These genetic variations are
called very important pharmacogenetic (VIP) variants and
listed in the pharmacogenomics databases such as the
Pharmacogenomics Knowledge Base (PharmGKB), the
Pharmacogenetics of Membrane Transporters (PMT)
database, and PharmaADME [6–8]. Currently, PharmGKB
(http://www.pharmgkb.org) is the most comprehensive
database and dedicates to propagating primary pharma-
cogenomic data and knowledge. They have extensively
annotated the vital drug response genes and presented this
information in VIP summaries, pathway diagrams, and cu-
rated literature [9].
In China, there are 56 different nationalities. Besides
Han, the others account for approximately 100 million
people. Due to the different genetic backgrounds and
diverse environments of these minor populations, we
distinguish them easily from the Han ethnicity. The
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Mongolian population represents one of the fifteen lar-
gest ethnic minorities in China [10]. They primarily live
in the Inner Mongolia, Liaoning, Heilongjiang and the
Xinjiang Uygur Autonomous Region. The areas are lo-
cated in the grassland region of Northern China and sig-
nificantly different with the Central Plains. Special living
environments of the Mongol people shaped their unique
gene distribution frequencies. An increasing number of
studies suggest that genes related to drug response vary
between different populations [11], so the pharmacogen-
omics population genetic studies of different population
is valuable.
In this study, we random selected and genotyped 85
VIP variants from the PharmGKB VIP database in 100
Mongols from Xinjiang. We designed primers using
MassARRAY Assay Design 3.0 Software [12]. We com-
pared the Mongol’s allele frequencies with 11 popula-
tions from 1000 genomes project and the Mongol’s
genotype frequencies and haplotype construction with
11 HapMap populations to identify the differences
among them. The results will expand the current Mongol
pharmacogenomic information and ethnic diversity. We
aimed to provide new strategies for medical professionals
through use genomic and molecular data to optimize drug
administration and therapeutic treatment in the future.
Methods
Ethics statement
Blood samples and signed informed consent forms were
obtained from all enrolls. All participants were informed
both verbally and in writing of the procedures and pur-
pose of the study, and signed informed consent docu-
ments. The clinical protocol was approved by the
Clinical Research Ethics of Xizang Minzu University and
Northwest University, and it is in compliance with De-
partment of Health and Human Services (DHHS) regu-
lations for human research subject protection.
Study participants
We recruited 100 random unrelated Mongol adults (50
males and 50 females, average age range 25-40 years)
from the Xinjiang Region of China and collected blood
samples. The detailed recruitment criteria are the sample
have good health body and had at least three generations
of exclusive ethnic ancestries. They rarely communicate
with other ethnics in Xinjiang because they are still no-
mads which living on relatively limited pasture. They
were determined to be a representative Mongol popula-
tion sample with regard to both ancestry and environ-
mental exposure.
Variant selection and genotyping
Using the PharmGKB database, we screened published
genetic polymorphisms associated with VIP variants, and
finally 85 genetic variant loci from 37 genes were ran-
domly selected for our investigation. We extracted gen-
omic DNA from whole blood using a GoldMag-Mini
Whole Blood Genomic DNA Purification Kit (GoldMag
Ltd. Xi’an, China) according to the manufacturer’s
protocol. The genomic DNA concentration was mea-
sured by absorbance at 260 nm using a NanoDrop
2000C (Thermo Scientific, Waltham, Massachusetts,
USA). We used the Sequenom MassARRAY Assay
Design 3.0 software (San Diego, California, USA) to de-
sign multiplexed SNP MassEXTEND arrays [12]. We
utilized a Sequenom MassARRAY RS1000 (San Diego,
California, USA) to genotype the SNPs according to the
manufacturer’s instructions. Sequenom Typer 4.0 Soft-
ware was used for data collection and analysis as described
previously [13].
Statistical analyses
We used Microsoft Excel and the SPSS 19.0 statistical pack-
age (SPSS, Chicago, IL) to perform a Hardy–Weinberg
Equilibrium (HWE) analysis and χ2 tests. All p values calcu-
lated were two-sided and Bonferroni’s multiple adjustment
was used to correction. The values were considered statisti-
cally significant when p < 0.05 and p < 0.05/(85 × 11), re-
spectively [14]. We analyzed each variant frequency in
Mongols using an exact test to identify those that departed
from HWE. We downloaded the allele frequencies of 85
loci in eleven randomly population of 1000 genomes pro-
ject, which are a population of African ancestry in the
southwestern USA (ASW); a population of Chinese Dai in
Xishuangbanna, China (CDX); a Utah residents population
(CEPH) with North and Western European Ancestry
(CEU); the Chinese Han in Beijing, China (CHB); the
Gujarati Indians in Houston, Texas, USA (GIH); the
Japanese population in Tokyo, Japan (JPT); the Luhya
people in Webuye, Kenya (LWK); people of Mexican ances-
try from Los Angeles, USA (MXL); a population of Puerto
Ricans from Puerto Rico (PUR); the Tuscan people of Italy
(TSI); and the Yoruba in Ibadan, Nigeria (YRI). We down-
loaded the genotype frequencies of 85 variation loci in
eleven populations from the HapMap database that are
ASW; a northwestern European population (CEU); CHB; a
Chinese population of metropolitan Denver, Colorado,
USA (CHD); GIH; JPT; LWK; people of Mexican ancestry
living in Los Angeles, California, USA (MEX); the Maasai
people in Kinyawa, Kenya (MKK); TSI; and YRI. We first
compared the allele frequencies difference between Mongo-
lian and 11 random 1000 genomes project popualtions and
calculate the correlation coefficient (R2) among the minor
different population, then compared and calculated the
selected SNP’s variant frequencies between the Mongol
people and eleven HapMap populations (data from the sec-
ond phase of HapMap: http://hapmap.ncbi.nlm.nih.gov)
using a χ2 test. Afterwards, we downloaded the SNP allele
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Table 1 Basic characteristics of the selected VIP variants from the PharmGKB database
SNP ID Genes Position Chr Categories Alleles Amino Acid Translation Mongol
Family Phase A B AA AB BB
rs1801131 MTHFR 11854476 1 Methylenetetrahydrofolate
reductase family
Phase I C A Glu429Ala 8 34 58
rs1801133 MTHFR 11856378 1 Phase I T C Ala222Val 9 39 52
rs890293 CYP2J2 60392494 1 Cytochrome P450 superfamily Phase I G T 0 95 5
rs3918290 DPYD 97915614 1 - PhaseI G A 100 0 0
rs6025 F5 169519049 1 - Others G A Arg534Gln 99 1 0
rs20417 PTGS2 186650321 1 - Phase I G C 97 0 3
rs689466 PTGS2 186650751 1 - Phase I A G 45 45 10
rs4124874 UGT1A1 234665659 2 UDP-glucuronosyltransferase
family
Phase II C A 10 46 44
rs10929302 UGT1A1 234665782 2 Phase II G A 65 30 5
rs4148323 UGT1A1 234669144 2 Phase II A G Gly71Arg 7 34 59
rs7626962 SCN5A 38620907 3 Sodium channel gene family Others G T Ser1103Tyr 100 0 0
rs1805124 SCN5A 38645420 3 Others G A Pro1090Leu 1 25 74
rs6791924 SCN5A 38674699 3 Others G A Arg34Cys 100 0 0
rs3814055 NR1I2 119500035 3 Nuclear receptor family Others C T 46 47 7
rs2046934 P2RY12 151057642 3 G-protein coupled receptor
family
Others T C 63 34 3
rs1065776 P2RY1 152553628 3 Others T C Ala19Ala 0 7 93
rs701265 P2RY1 152554357 3 Others G A Val262Val 9 52 39
rs975833 ADH1A 100201739 4 Alcohol dehydrogenase family Phase I G C 33 52 15
rs2066702 ADH1B 100229017 4 Phase I C T Arg370Cys 100 0 0
rs1229984 ADH1B 100239319 4 Phase I G A His48Arg 45 44 11
rs698 ADH1C 100260789 4 Phase I A G Ile350Val 67 25 7
rs17244841 HMGCR 74642855 5 - Phase I A T 99 1 0
rs3846662 HMGCR 74651084 5 - Phase I T C 30 52 18
rs17238540 HMGCR 74655498 5 - Phase I T G 100 0 0
rs1042713 ADRB2 148206440 5 Adrenergic receptors family Phase I G A Arg16Gly 26 53 21
rs1042714 ADRB2 148206473 5 Phase I G C Gln27Glu 6 42 52
rs1800888 ADRB2 148206885 5 Phase I C T Thr164Ile 99 0 0
rs1142345 TPMT 18130918 6 Methyltransferase superfamily Phase II G A Tyr240Cys 0 2 98
rs1800460 TPMT 18139228 6 Phase II A G Ala154Thr 0 1 99
rs2066853 AHR 17379110 7 - Others G A Arg554Lys 35 48 16
rs1045642 ABCB1 87138645 7 ATP-binding cassette (ABC)
transporters superfamily
Others T C Ile1145Ile 17 47 36
rs2032582 ABCB1 87160618 7 Others G T Ser893Ala 25 35 15
rs2032582 ABCB1 87160618 7 Others G A Ser893Thr 25 10 2
rs2032582 ABCB1 87160618 7 Others T A 15 13 2
rs1128503 ABCB1 87179601 7 Others T C Gly412Gly 37 48 13
rs10264272 CYP3A5 99262835 7 Cytochrome P450 superfamily Phase I C T Lys208Lys 100 0 0
rs776746 CYP3A5 99270539 7 Phase I G A 79 20 1
rs4986913 CYP3A4 99358459 7 Phase I C T Pro467Ser 100 0 0
rs4986910 CYP3A4 99358524 7 Phase I T C Met445Thr 100 0 0
rs4986909 CYP3A4 99359670 7 Phase I C T Pro416Leu 100 0 0
rs12721634 CYP3A4 99381661 7 Phase I T C Leu15Pro 100 0 0
rs2740574 CYP3A4 99382096 7 Phase I A G 97 2 1
rs3815459 KCNH2 150644394 7 Eag family Others A G 40 48 12
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Table 1 Basic characteristics of the selected VIP variants from the PharmGKB database (Continued)
rs36210421 KCNH2 150644428 7 Others G T Arg707Leu 100 0 0
rs12720441 KCNH2 150647304 7 Others C T Arg444Trp 100 0 0
rs3807375 KCNH2 150667210 7 Others A G 56 37 7
rs4986893 CYP2C19 96540410 10 Cytochrome P450 superfamily Phase I G A Trp212null 88 11 1
rs4244285 CYP2C19 96541616 10 Phase I G A Pro227Pro 69 26 5
rs1799853 CYP2C9 96702047 10 Phase I C T Arg144Cys 100 0 0
rs1801252 ADRB1 115804036 10 Adrenergic receptors family Phase I G A Ser49Gly 5 26 69
rs1801253 ADRB1 115805056 10 Phase I C G Gly389Arg 69 26 4
rs5219 KCNJ11 17409572 11 Inward-rectifier potassium
channel family
Others C T Lys23Glu 39 54 7
rs1695 GSTP1 67352689 11 Glutathione S-transferase family Phase II A G Ile105Val 52 46 2
rs1138272 GSTP1 67353579 11 Phase II T C Ala114Val 0 3 97
rs1800497 ANKK1 113270828 11 Ser/Thr protein kinase family Phase I T C Glu713Lys 7 40 51
rs6277 DRD2 113283459 11 G-protein coupled receptor
family
Others C T Pro290Pro 79 19 2
rs4149056 SLCO1B1 21331549 12 Solute carrier family Others T C Val174Ala 71 28 1
rs7975232 VDR 48238837 12 Nuclear receptor family Others C A 42 51 7
rs1544410 VDR 48239835 12 Others G A 72 26 2
rs2239185 VDR 48244559 12 Others T C 7 51 42
rs1540339 VDR 48257326 12 Others G A 18 49 33
rs2239179 VDR 48257766 12 Others A G 46 43 11
rs3782905 VDR 48266167 12 Others C G 62 35 2
rs2228570 VDR 48272895 12 Others T C Met51Arg, Met51Lys,
Met51Thr
9 51 40
rs10735810 VDR 48272895 12 Others C T 38 40 9
rs11568820 VDR 48302545 12 Others G A 55 36 7
rs1801030 SULT1A1 28617485 16 Sulfotransferase family Phase II A G Val223Met 100 0 0
rs3760091 SULT1A1 28620800 16 Phase II C G 32 43 18
rs7294 VKORC1 31102321 16 - Phase I G A 67 32 1
rs9934438 VKORC1 31104878 16 - Phase I G A 2 35 63
rs28399454 CYP2A6 41351267 19 Cytochrome P450 superfamily Phase I G A Val365Met 100 0 0
rs28399444 CYP2A6 41354190 19 Phase I AA - Glu197Ser, Glu197Arg 100 0 0
rs1801272 CYP2A6 41354533 19 Phase I T A Leu160His 95 3 0
rs28399433 CYP2A6 41356379 19 Phase I G T 1 20 79
rs3745274 CYP2B6 41512841 19 Phase I G T Gln172His 65 29 6
rs28399499 CYP2B6 41518221 19 Phase I T C Ile328Thr 99 1 0
rs3211371 CYP2B6 41522715 19 Phase I C T Arg487Cys 0 100 0
rs12659 SLC19A1 46951556 21 Solute carrier family Others C T Pro192Pro 19 51 30
rs1051266 SLC19A1 46957794 21 Others G A His27Arg 18 50 31
rs1131596 SLC19A1 46957916 21 Others T C 19 38 24
rs4680 COMT 19951271 22 - Phase II A G Val158Met 10 38 52
rs59421388 CYP2D6 42523610 22 Cytochrome P450 superfamily Phase I C T Val287Met 100 0 0
rs28371725 CYP2D6 42523805 22 Phase I G A 86 13 0
rs16947 CYP2D6 42523943 22 Phase I G A 44 35 0
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frequencies of selected loci from the ALlele FREquency
Database (http://alfred.med.yale.edu, ALFRED) and ana-
lyzed the global genetic variation patterns. We used
Haploview software package (4.2) to perform the linkage
disequilibrium (LD) analysis constructed haplotype, and
genetic association of significant polymorphism loci.
Analysis of population genetic structures
There are studies proved that the center of study which re-
search human origins, DNA forensics and complex diseases
is population genetic structure. It is also important to our
study as a pharmacogenomics population study. Structure
analysis is common in population genetic study. To further
investigate variation at the VIP locus in terms of population
structure we used STRUCTURE ver. 2.3.1 (Pritchard Lab,
Stanford University,USA, http://pritchardlab.stanford.edu/
structure.html) which based on the Bayesian clustering
algorithmto assign the samples within a hypothetical K
number of populations hypothesized by Pritchard et al [15].
We performed structure analysis using ancestry model with
correlated allele frequencies among clusters. K = 2 to 8 is
the range of possible numbers of clusters and 12 trials were
run for each K. We performed the MCMC analyses for
each structure analysis was run for 10,000 after an initial
burn-in period of 10,000 for data collection. △K was calcu-
lated to identified the most likely number of clusters by
STRUCTURE HARVESTER [16].
Results
We sequenced 85 VIP variants from 100 Mongols. The
selected SNP PCR primers were designed using the
Sequenom MassARRAY Assay Design 3.0 Software. In-
formation regarding the selected VIP loci and their
genotype frequencies is listed in Table 1, including the
genes, their positions, the nucleotide change, the amino
acid translation, the calculated allele frequencies, and
the genotype frequencies for Mongols. Several variants,
such as rs698, rs1695, rs5219, rs16974, rs20417,
rs890293, rs2740574, and rs3211371, did not meet HWE
with a 5 % significance level and were not included in
the final 85 loci analyzed. We first compared the allele
frequencies differences among the Mongols and the se-
lected 11 groups from 1000 genomes project database
(p < 0.05). We found that there are some loci have sig-
nificantly different between them. In ASW population,
there are 22 loci exist different with Mongol. The results
of other groups are as follows: CDX, 14; CEU, 19;
CHB,15; GIH,15; JPT,15; LWK,18; MXL,18; PUR, 22;
TSI, 18; YRI, 18(Table 2), respectively. In Fig. 1, we se-
lected CDX, CHB and JPT which are the minimum dif-
ference population compared with Mongol population
to calculate the correlation coefficient, R2. From the al-
lele frequencies difference comparison, we figure out
one initial conclusion that the Mongolian is relatively
close to CDX, followed by CHB and JPT.
We used χ2 analyses to compare differences in the vari-
ants’ genotype frequency distributions among the Mongols
and eleven HapMap populations (without adjustment, p <
0.05; adjustment, p < 0.05/85 × 11). There were a number
of loci had significantly different distribution frequencies
among Mongols and the 11 HapMap populations that
listed in Table 3 Without adjustment the ASW population
had 20 different loci; CEU, 27; CHB, 19; CHD, 10; GIH,
24; JPT, 17; LWK, 24; MEX, 17; MKK, 22; TSI, 14; and
YRI, 38. Once the data underwent multiple comparison
adjustment, the numbers of significantly different loci
variants were revised to 13, 13, 6, 1, 8, 5, 18, 3, 18, 6 and
26, respectively.
When p < 0.05, rs1540339 locus (46489G > A) which
located in an intron region of VDR (1, 25- dihydroxyvi-
tamin D3 receptor), showed the greatest number of sig-
nificant differences between Mongol and 11 HapMap
populations; the SNP rs776746 (12083G > A) is a SNP of
CYP3A5 which located in an intron region and a signifi-
cant locus that observed in these populations except
TSI. After Bonferroni’s multiple adjustment (p < 0.05/
(85 × 11)), the number of HapMap populations with a
significantly different rs1540339 locus changed very
large which included CEU, CHB, CHD, JPT, MEX and
TRI. The rs776746 locus also changed very large which
except TSI added CEU, CHD, GIH, JPT and MEX.
Of the 85 variants analyzed, 74 could be classified as
part of a superfamily. When the gene superfamily cat-
egories were tallied, the number of the associated vari-
ants with significantly different frequencies between the
Mongols and the eleven HapMap populations were as
follows: ASW, 10; CEU, 9; CHB, 5; CHD, 1; GIH, 5; JPT,
4; LWK, 14; MEX, 1; MKK, 14; TSI, 4; and YRI, 21
(Table 4). A number of distinct loci were significantly
different and included several pharmacogenomic super-
families such as the nuclear receptor family, the sodium
channel gene family, and the methylenetetrahydrofolate
reductase family.
To further verify the ubiquitous differences between dif-
ferent groups through research the difference of maximum
and minimum of two SNPs, we selected two variants, the
Table 1 Basic characteristics of the selected VIP variants from the PharmGKB database (Continued)
rs61736512 CYP2D6 42525134 22 Phase I C A/G/T Val136Met 100 0 0
rs28371706 CYP2D6 42525772 22 Phase I C T Thr107Ile 100 0 0
rs5030656 CYP2D6 42524176:42524176 22 Phase I AAG - 100 0 0
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Table 2 Significant VIP variants in Mongols compared with the eleven populations which selected from 1000 genomes project
SNP ID p < 0.05
ASW CDX CEU CHB GIH JPT LWK MXL PUR TSI YRI
rs10264272 1.42E-05 - - - - - 1.01E-01 1.35E-10 3.35E-06 7.27E-48 3.30E-02
rs1042713 1.90E-01 2.05E-01 2.09E-01 1.90E-01 1.74E-01 1.70E-01 1.63E-01 1.57E-01 1.84E-01 2.00E-01 1.83E-01
rs1042714 1.29E-01 1.31E-01 2.37E-01 1.30E-01 1.17E-01 1.32E-01 1.19E-01 1.27E-01 1.95E-01 1.87E-01 1.29E-01
rs1045642 2.25E-01 1.59E-01 2.35E-01 1.58E-01 2.36E-01 1.88E-01 2.43E-01 1.86E-01 1.61E-01 1.81E-01 2.49E-01
rs1051266 1.54E-01 1.67E-01 2.22E-01 1.98E-01 2.41E-01 1.64E-01 2.01E-01 2.65E-01 2.20E-01 2.12E-01 1.93E-01
rs1065776 7.08E-02 1.10E-05 8.68E-04 1.09E-04 8.98E-03 2.49E-03 7.70E-02 4.22E-04 4.99E-03 9.58E-05 8.60E-02
rs10735810 4.49E-01 2.18E-01 2.79E-01 2.83E-01 3.77E-01 3.30E-01 4.69E-01 2.42E-01 3.16E-01 3.10E-01 4.55E-01
rs10929302 1.62E-01 7.71E-02 1.47E-01 7.55E-02 2.47E-01 7.73E-02 1.85E-01 1.74E-01 1.61E-01 1.00E-01 1.87E-01
rs1128503 4.27E-01 1.45E-01 2.53E-01 1.68E-01 1.73E-01 1.56E-01 4.73E-01 2.29E-01 2.69E-01 2.59E-01 4.48E-01
rs1131596 1.94E-01 1.59E-01 2.04E-01 1.81E-01 2.21E-01 1.61E-01 2.56E-01 2.42E-01 2.00E-01 1.94E-01 2.37E-01
rs1138272 4.98E-07 6.87E-16 4.54E-03 6.87E-16 2.20E-03 6.87E-16 6.75E-09 2.13E-04 6.74E-06 1.43E-04 6.87E-16
rs1142345 4.41E-03 1.55E-06 8.22E-07 2.81E-16 7.94E-08 5.19E-09 9.34E-03 4.20E-05 3.05E-03 9.93E-11 2.63E-04
rs11568820 4.50E-01 1.56E-01 1.09E-01 2.10E-01 1.89E-01 2.38E-01 5.72E-01 1.15E-01 1.13E-01 1.06E-01 6.86E-01
rs1229984 2.02E-01 3.25E-01 2.00E-01 3.79E-01 1.98E-01 3.96E-01 2.02E-01 1.88E-01 1.92E-01 1.94E-01 2.02E-01
rs12659 2.31E-01 1.65E-01 2.21E-01 1.88E-01 2.51E-01 1.60E-01 1.66E-01 2.62E-01 2.19E-01 2.09E-01 1.90E-01
rs12720441 1.00E + 00 1.00E + 00 1.00E + 00 1.00E + 00 1.00E + 00 1.00E + 00 1.00E + 00 1.00E + 00 1.00E + 00 1.00E + 00 1.00E + 00
rs1540339 3.35E-01 1.98E-01 2.90E-01 2.11E-01 2.72E-01 2.17E-01 4.10E-01 2.53E-01 2.82E-01 2.69E-01 3.65E-01
rs1544410 1.27E-01 3.56E-02 2.98E-01 3.26E-02 2.59E-01 4.48E-02 1.13E-01 7.41E-02 2.43E-01 2.49E-01 1.47E-01
rs16947 2.23E-01 9.14E-02 1.54E-01 9.11E-02 2.41E-01 9.15E-02 4.12E-01 1.10E-01 2.01E-01 1.90E-01 3.38E-01
rs1695 2.42E-01 1.06E-01 1.95E-01 1.09E-01 1.39E-01 1.14E-01 2.81E-01 3.22E-01 1.79E-01 1.29E-01 1.98E-01
rs17238540 3.20E-03 - 1.07E-15 - - - 2.03E-03 9.22E-07 1.14E-12 6.91E-08 2.99E-03
rs17244841 3.79E-03 4.44E-45 2.57E-12 4.44E-45 4.44E-45 1.82E-10 1.81E-03 3.30E-06 8.88E-13 4.29E-07 2.75E-03
rs1799853 1.71E-06 - 2.34E-02 - 1.22E-05 - - 3.82E-03 1.69E-02 2.50E-02 -
rs1800460 9.41E-09 4.44E-45 1.66E-07 4.44E-45 4.44E-45 4.44E-45 4.44E-45 3.30E-06 2.57E-05 5.05E-13 4.44E-45
rs1800497 2.14E-01 2.22E-01 1.24E-01 2.16E-01 1.20E-01 1.84E-01 1.77E-01 2.16E-01 1.19E-01 1.22E-01 1.86E-01
rs1800888 - - 1.07E-15 - - - - - - 6.14E-17 -
rs1801131 1.07E-01 1.26E-01 1.51E-01 1.05E-01 2.12E-01 1.10E-01 1.09E-01 1.11E-01 1.06E-01 1.41E-01 1.13E-01
rs1801133 1.40E-01 1.40E-01 1.25E-01 2.32E-01 1.38E-01 1.74E-01 1.46E-01 2.34E-01 2.19E-01 2.33E-01 1.43E-01
rs1801252 6.55E-02 6.41E-02 6.28E-02 6.45E-02 6.35E-02 6.43E-02 1.47E-01 1.15E-01 8.73E-02 5.96E-02 8.24E-02
rs1801253 2.01E-01 8.00E-02 1.68E-01 8.58E-02 9.53E-02 6.70E-02 1.53E-01 6.09E-02 9.70E-02 1.82E-01 2.94E-01
rs1801272 9.73E-01 9.83E-01 9.43E-01 9.83E-01 9.72E-01 9.83E-01 9.83E-01 9.65E-01 9.77E-01 9.30E-01 9.83E-01
rs1805124 1.22E-01 2.93E-02 6.49E-02 3.75E-02 7.93E-02 3.85E-02 1.55E-01 5.42E-02 1.20E-01 1.00E-01 1.77E-01
rs20417 6.15E-01 9.18E-01 7.73E-01 9.06E-01 7.81E-01 9.17E-01 6.48E-01 7.29E-01 7.28E-01 8.22E-01 5.42E-01
rs2046934 7.68E-02 7.56E-02 7.82E-02 7.93E-02 7.48E-02 7.71E-02 7.48E-02 7.54E-02 7.44E-02 7.61E-02 7.73E-02
rs2066702 6.37E-02 - - - - - 1.79E-02 3.41E-08 2.32E-10 - 1.45E-01
rs2066853 1.69E-01 1.99E-01 2.60E-01 1.58E-01 2.51E-01 1.79E-01 1.94E-01 2.45E-01 2.39E-01 2.58E-01 1.75E-01
rs2228570 1.75E-01 2.40E-01 1.84E-01 1.80E-01 1.51E-01 1.43E-01 1.82E-01 2.17E-01 1.53E-01 1.58E-01 1.77E-01
rs2239179 1.37E-01 1.44E-01 2.39E-01 1.54E-01 2.39E-01 1.59E-01 1.47E-01 1.38E-01 1.99E-01 1.80E-01 1.39E-01
rs2239185 2.69E-01 1.33E-01 3.05E-01 1.41E-01 2.42E-01 1.32E-01 3.30E-01 1.82E-01 2.94E-01 2.96E-01 2.92E-01
rs2740574 6.05E-01 3.29E-12 8.71E-08 3.29E-12 1.99E-03 3.29E-12 7.90E-01 1.22E-03 5.35E-02 4.58E-06 7.11E-01
rs28371706 2.11E-02 - - - - - 5.24E-02 - 3.96E-24 - 1.14E-01
rs28371725 7.01E-04 7.46E-03 2.18E-02 1.65E-03 3.43E-02 3.16E-04 1.41E-03 6.68E-04 2.13E-02 3.39E-02 4.43E-04
rs28399433 2.33E-02 6.01E-02 1.44E-02 1.27E-01 6.80E-02 1.37E-01 2.10E-02 2.26E-02 2.25E-02 1.69E-02 2.27E-02
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most significantly different variants – rs1540339, rs1801131
which is one of the least significantly loci distributed in all
12 populations, and downloaded the population data from
the ALFRED database. Combining the new data, we carried
out a global analysis. Figure 2 shows the global frequency
data of rs1801131 and Fig. 3, the rs1540339 data. From the
two figures, we only found that the frequency of Mongol is
relatively close to the populations distributed in East Asia.
Meanwhile, we focused on rs1540339 to explore the
difference of the haplotypes. We performed the LD ana-
lysis to define blocks and haplotypes of VDR gene which
include rs1540339, rs7975232, rs1544410, rs2239179,
Table 2 Significant VIP variants in Mongols compared with the eleven populations which selected from 1000 genomes project
(Continued)
rs28399454 5.13E-04 - - - - - 4.87E-05 - 3.96E-24 - 1.45E-02
rs28399499 3.79E-03 4.44E-45 4.44E-45 4.44E-45 4.44E-45 4.44E-45 1.77E-04 9.37E-19 1.82E-10 4.44E-45 8.27E-03
rs3211371 3.94E-01 4.14E-01 3.57E-01 4.14E-01 3.56E-01 4.08E-01 4.14E-01 3.63E-01 3.57E-01 3.50E-01 4.08E-01
rs36210421 - - 6.00E-06 - 5.70E-46 6.74E-47 - 2.15E-29 - 6.14E-17 -
rs3745274 1.79E-01 1.61E-01 1.26E-01 8.04E-02 2.18E-01 8.94E-02 1.83E-01 1.50E-01 1.74E-01 1.43E-01 2.17E-01
rs3760091 1.69E-01 1.79E-01 1.60E-01 1.64E-01 2.31E-01 1.65E-01 1.82E-01 1.78E-01 1.68E-01 1.85E-01 1.79E-01
rs3782905 5.54E-01 6.44E-01 4.26E-01 6.28E-01 5.24E-01 6.82E-01 5.48E-01 5.66E-01 4.68E-01 4.46E-01 5.58E-01
rs3807375 1.14E-01 1.07E-01 3.91E-01 1.06E-01 3.59E-01 1.11E-01 1.11E-01 2.19E-01 3.31E-01 3.97E-01 1.08E-01
rs3814055 1.27E-01 1.53E-01 1.43E-01 1.31E-01 1.91E-01 1.35E-01 1.25E-01 1.42E-01 1.89E-01 1.56E-01 1.31E-01
rs3815459 2.70E-01 1.82E-01 4.25E-01 1.61E-01 3.22E-01 1.87E-01 2.89E-01 2.83E-01 3.54E-01 3.97E-01 3.27E-01
rs3846662 3.96E-01 1.86E-01 1.60E-01 1.90E-01 2.68E-01 1.97E-01 4.66E-01 1.55E-01 1.85E-01 1.58E-01 4.58E-01
rs3918290 5.03E-28 - 3.18E-44 - 2.72E-16 - - - - 7.27E-48 -
rs4124874 4.33E-01 2.03E-01 1.92E-01 1.47E-01 3.05E-01 1.37E-01 5.27E-01 2.44E-01 2.24E-01 1.98E-01 5.38E-01
rs4148323 9.94E-02 1.05E-01 9.82E-02 9.89E-02 1.01E-01 1.05E-01 9.82E-02 1.01E-01 9.82E-02 9.82E-02 9.82E-02
rs4149056 3.68E-02 4.68E-02 4.74E-02 4.64E-02 2.73E-02 4.48E-02 2.74E-02 3.90E-02 4.48E-02 8.70E-02 2.48E-02
rs4244285 6.40E-02 1.19E-01 6.35E-02 1.72E-01 1.68E-01 1.62E-01 8.47E-02 6.31E-02 6.34E-02 6.01E-02 6.53E-02
rs4680 1.23E-01 1.23E-01 2.29E-01 1.34E-01 2.10E-01 1.20E-01 1.20E-01 1.85E-01 1.85E-01 1.54E-01 1.54E-01
rs4986893 1.93E-04 6.14E-03 1.93E-04 2.27E-03 2.96E-04 5.46E-03 4.39E-04 1.93E-04 1.93E-04 1.93E-04 1.93E-04
rs4986910 5.03E-28 - 1.07E-15 - - - - - 6.74E-47 - -
rs4986913 - - - - 5.70E-46 - - - - - -
rs5219 1.85E-01 1.64E-01 1.59E-01 1.57E-01 1.79E-01 1.38E-01 2.13E-01 1.72E-01 1.49E-01 1.49E-01 2.14E-01
rs59421388 1.71E-06 - - - - - 3.66E-02 - 6.74E-47 - 4.90E-03
rs6025 4.44E-45 4.44E-45 1.42E-08 4.44E-45 7.17E-24 4.44E-45 4.44E-45 9.37E-19 1.36E-16 2.56E-24 4.44E-45
rs61736512 1.71E-06 - - - - - 3.66E-02 - 6.74E-47 - 6.07E-03
rs6277 4.28E-02 1.69E-02 3.46E-01 1.42E-02 1.87E-01 2.09E-02 9.87E-03 1.66E-01 2.93E-01 4.45E-01 1.22E-02
rs6791924 6.55E-05 - - - - - 2.96E-02 1.35E-10 3.96E-24 - 1.66E-03
rs689466 1.74E-01 2.50E-01 1.61E-01 2.17E-01 1.75E-01 1.99E-01 1.92E-01 1.47E-01 1.50E-01 1.60E-01 1.85E-01
rs698 7.48E-02 7.35E-02 2.80E-01 6.65E-02 1.29E-01 6.98E-02 7.49E-02 1.29E-01 1.91E-01 1.48E-01 6.94E-02
rs701265 3.38E-01 1.81E-01 1.87E-01 1.55E-01 1.76E-01 1.58E-01 4.38E-01 1.77E-01 1.65E-01 1.88E-01 4.39E-01
rs7294 2.93E-01 5.96E-02 1.57E-01 4.55E-02 4.69E-01 5.39E-02 2.53E-01 1.88E-01 1.79E-01 1.75E-01 3.28E-01
rs7626962 6.55E-05 - - - - - 1.98E-08 - 1.68E-16 - 1.18E-03
rs776746 5.43E-01 1.66E-01 1.26E-02 1.66E-01 1.36E-01 1.17E-01 7.44E-01 1.01E-01 1.25E-01 1.45E-02 6.95E-01
rs7975232 3.26E-01 1.42E-01 3.01E-01 1.41E-01 2.46E-01 1.37E-01 3.90E-01 1.77E-01 2.94E-01 2.96E-01 3.05E-01
rs890293 3.42E-01 4.34E-01 4.12E-01 4.16E-01 4.10E-01 4.29E-01 3.58E-01 4.24E-01 4.04E-01 4.11E-01 3.48E-01
rs975833 2.05E-01 3.46E-01 2.09E-01 3.72E-01 1.91E-01 3.80E-01 2.28E-01 2.50E-01 2.17E-01 1.99E-01 1.88E-01
rs9934438 6.28E-01 7.43E-02 3.64E-01 6.42E-02 6.01E-01 7.08E-02 7.79E-01 3.29E-01 3.99E-01 3.22E-01 7.49E-01
aItalics indicated that after adjustment p < 0.05 the locus has statistically significant
bThe results has not the mathematics sense
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rs10735810 and rs11568820 by Haploview. The six SNPs
selected from our lists and all of them have the HapMap
data. Figure 4 shown that Mongol and CHB has only
one block which consisted by rs1540339 and rs2239179,
others has obviously different blocks compared with
Mongol.
For further clarified the genetic structure of Mongol and
different populations, we used Structure 2.3.1 performed
the population genetic structure comparisons by which
works well for 85 loci (K = 2–8). The results are indicated
by K = 3–5 (Fig. 5), which based on the Estimated Ln Prob
of Data and other recommendations of the STRUCTURE
software manual, When k = 3, individuals were divided in
three affinity groups (subgroups 1: Mongol, CHD, JPT,
CHB; subgroup 2: MEX, TSI, GIH, CEU; subgroup 3:
MKK, ASW, LWK, YRI.) which used relative majority of
likelihood assignment of individuals to subgroup.
Followed by more K value to run STRUCTURE and then
displayed the results in bar plots. From the image
when k = 4 and 5, we easily found Mongol is closest to
CHD, followed by CHB, JPT, and existed significant gen-
etic structure differences with GIH and MEX.
Discussion
Personalized or stratified healthcare is an important goal
for medicine in the 21st century. It ensures that the
treatments of patients are safe and efficacious [17]. With
the rapid development of pharmacogenetics, serious at-
tention has been paid to interethnic or interracial differ-
ences in drug responses with the intent to identify the
genetic backgrounds of these variations [18]. Our study
analyzed the distribution of these VIP variant allele and
genotype frequencies to seek out which are altered
among the different human populations [19], and found
that even the SNP of smallest difference also had signifi-
cant diversity between different groups. Through the
comprehensive analysis, we revealed that Mongol and
Chinese populations have the minimum difference.
Two of the variants were identified, rs1801133 (C677T)
and rs1801131 (A1298C), included one of the least
significant locus in our data, they are located in the same
gene – methylenetetrahydrofolate reductase (MTHFR)
gene. MTHFR is located on chromosome 1p36.3 in human
which is an important regulatory enzyme that in-
volved in the folate pathway. It catalyzes the conversion of
Fig. 1 Pairwise comparisons of difference in correlation coefficient value R2
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Table 3 Significant VIP variants in Mongols compared with the eleven HapMap populations after Bonferroni’s multiple adjustment
SNP ID p < 0.05/(85 × 11)
ASW CEU CHB CHD GIH JPT LWK MEX MKK TSI YRI
rs10264272 - - - - - - 1.44532E-12a -b 8.82E-08 - 8.95E-09
rs1042713 0.27747316 0.04538453 0.20742869 0.12421983 0.47741241 0.58439074 0.54885721 0.90201422 0.32444254 0.01651791 0.32052007
rs1042714 - 8.50E-05 0.0164067 - - 0.00044539 - - - - 0.07513803
rs1045642 4.92E-09 0.00116183 0.54603257 0.29771668 0.00162633 0.28558754 - 0.45392674 1.61E-08 0.50240513 2.41E-10
rs1051266 0.2807523 0.01941254 0.33010486 0.12007109 0.00246504 0.95743171 0.00188424 0.00059997 1.36E-05 0.07011082 0.01298312
rs1065776 - - - - - - - - - - -
rs10735810 0.01884334 0.19825318 0.35306461 0.01687974 0.42789254 0.16219036 0.00044495 0.00959988 0.00592383 0.43490023 0.00575742
rs10929302 - 0.2213663 0.06968442 - - 0.08008041 - - - - 0.00749071
rs1128503 3.62E-11 0.00100994 0.18626034 0.47475329 0.86444934 0.72437343 9.47E-20 0.0231531 1.73E-21 0.00083246 2.91E-21
rs1131596 - - - - - - - - - - -
rs1138272 - - - - - - - 0.03123952 - - -
rs1142345 - - - - - - 0.00012785 0.01252136 - - 0.1353563
rs11568820 8.07E-12 0.39713354 0.00088999 0.06850479 0.00681425 0.00038384 3.81E-24 0.46841122 8.28E-23 0.75222572 9.16E-37
rs1229984 - 1.20E-11 5.49E-10 - - 7.68E-09 - - - - 1.69E-11
rs12659 - - - - - - - - - - -
rs12720441 - - - - - - - - - - -
rs12721634 - - - - - - - - - - -
rs1540339 6.30E-07 0.000116 0.02314118 0.00276558 5.31E-05 0.0048091 1.48E-15 0.01115187 7.82E-16 0.00014778 1.52E-12
rs1544410 0.06188271 1.69E-08 0.00273242 0.00242682 3.33E-08 0.39727054 0.04804346 0.14153371 2.63E-06 2.71E-07 0.00553292
rs16947 - - - - - - - - - - -
rs1695 0.00017138 0.0007169 0.21785447 0.42376541 0.07372284 6.16E-05 2.60E-07 6.20E-08 0.00864594 0.15360318 0.00135975
rs17238540 - - - - - - - - - - -
rs17244841 - - - - - - - - - - -
rs1799853 - - - - - - - - - - -
rs1800460 - - - - - - - - - - -
rs1800497 0.05635435 0.10573707 0.01289027 0.00481115 0.55312005 0.02909995 0.16955696 0.04539287 0.16542808 0.29503104 0.01419286
rs1800888 - - - - - - - - - - -
rs1801030 - - - - - - - - - - -
rs1801131 0.29838721 0.10171883 0.44379999 0.64433884 0.0183119 0.20392711 0.2737931 0.64086028 0.91251575 0.36340669 0.00184881
rs1801133 0.00034783 0.72955982 0.00135396 0.49992159 0.0319354 0.23529674 1.68E-05 0.05835697 1.52E-07 0.00349079 4.10E-06
rs1801252 - - 0.0001403 - - 0.0001681 - - - - 4.90E-05












Table 3 Significant VIP variants in Mongols compared with the eleven HapMap populations after Bonferroni’s multiple adjustment (Continued)
rs1801272 - 2.63E-33 1.46E-31 - - 2.42E-30 - - - - 4.91E-35
rs1805124 0.02658648 0.36484631 0.54483156 0.22673707 0.35376474 0.6491555 0.00245978 0.86877609 1.87E-06 0.04053952 0.00013843
rs2032582 2.07E-07 0.46831684 0.02691764 0.0899833 0.00032517 0.11450139 5.66E-17 0.70811234 6.28E-14 0.96126181 -
rs2032582 - - - - - - - - - - -
rs2032582 - - - - - - - - - - -
rs20417 - 1.04E-29 2.19E-29 - - 3.82E-29 - - - - 2.24E-24
rs2046934 - 0.84184132 0.87995183 - - 0.97034167 - - - - 0.77148622
rs2066702 1.06E-10 - - - - - 4.08E-07 - - - 5.65E-15
rs2066853 0.65615202 1.66E-11 0.94214103 0.94774007 2.18E-09 0.49230972 0.2116787 5.48E-06 0.41238266 9.43E-11 0.62463192
rs2228570 - - - - - - - - - - -
rs2239179 0.19236008 0.00467976 0.16879391 0.0735274 0.00371014 0.07153574 4.11E-08 0.71139635 0.04517466 0.17315647 0.71742841
rs2239185 - - 0.11123339 - - 0.45274301 - - - - 0.0001787
rs2740574 - - - - - - - - - - -
rs28371706 - - - - - - - - - - -
rs28371725 - - - - - - - - - - -
rs28399433 - - - - - - - - - - -
rs28399444 - - - - - - - - - - -
rs28399454 - - - - - - - - - - -
rs28399499 0.00193936 - - - - - - - 0.43590356 - 9.04E-06
rs3211371 - - - - - - - - - - -
rs36210421 - - - - - - - - - - -
rs3745274 0.12627303 0.2056118 0.70303194 0.34150665 0.00017843 0.84757978 0.04657355 0.04107996 0.00024687 0.1559596 2.11E-05
rs3760091 - - - - - - - - - - -
rs3782905 - 4.47E-15 4.87E-18 - - 1.49E-22 - - - - 4.87E-19
rs3807375 0.43616954 2.01E-12 0.86962796 0.83584673 8.18E-11 0.12181871 0.12372447 0.01752245 0.5934107 2.36E-12 0.57322879
rs3814055 0.83102212 0.52973507 0.45387793 0.20572098 0.03703383 0.18923006 0.29073405 0.7548396 0.05268438 0.26051487 0.09961755
rs3815459 - - 0.3754275 - - 0.00773141 - - - - 8.65E-06
rs3846662 8.13E-12 0.6759055 0.19583564 0.0971148 0.00018701 0.15042586 3.46E-24 0.45840601 2.29E-17 0.72844286 2.62E-26
rs3918290 - - - - - - - - - - -
rs4124874 1.52E-11 0.0357679 0.20056719 0.8982781 4.02E-07 0.89376825 3.20E-22 0.00572364 6.38E-23 0.14836683 3.23E-27
rs4148323 - 6.57E-08 0.11727653 1.15E-20 3.34E-08 0.02782333 - 7.78E-05 - - 6.57E-08
rs4149056 0.01202321 0.99516204 0.98870047 0.36757664 6.12E-05 0.19624085 1.43E-05 0.19712962 0.36973702 0.20946995 1.34E-07












Table 3 Significant VIP variants in Mongols compared with the eleven HapMap populations after Bonferroni’s multiple adjustment (Continued)
rs4680 0.48647969 0.00082072 0.98587091 0.14463711 0.04170753 0.66470326 0.78746668 0.23399959 0.94982091 0.00298993 0.57419215
rs4986893 - - - - - - - - - - -
rs4986909 - - - - - - - - - - -
rs4986910 - - - - - - - - - - -
rs4986913 - - - - - - - - - - -
rs5030656 - - - - - - - - - - -
rs5219 - - - - - - - - - - -
rs59421388 - - - - - - - - - - -
rs6025 - 0.42877395 - - - - - - - - -
rs61736512 - - - - - - - - - - -
rs6277 - 1.03E-13 0.29571877 - - 0.24782281 - - - - 0.052309
rs6791924 - - - - - - - - - - -
rs689466 0.00012294 0.00040262 0.00388527 0.02658023 0.00036352 0.031278 9.46E-12 0.34461035 1.46E-16 0.00281474 3.77E-08
rs698 0.67209493 3.15E-08 0.00098605 0.00686794 0.18843861 0.00282244 0.51518149 0.14164572 0.31894381 0.05936975 0.00044968
rs701265 1.10E-07 0.00028496 0.22430801 0.08574165 0.01840946 0.09399066 1.48E-16 0.00740647 6.36E-16 4.43E-05 3.39E-18
rs7294 3.00E-09 3.54E-05 0.00145857 0.01140667 2.58E-21 0.1101385 3.98E-08 0.00317685 1.58E-11 0.00047099 3.28E-12
rs7626962 - - - - - - - - - - 0.0012409
rs776746 3.55E-17 0.01253767 5.28E-05 0.00537234 0.00294358 0.00027677 6.11E-31 0.00270059 2.59E-17 0.10945504 2.12E-34
rs7975232 5.21E-07 6.63E-07 0.17255518 0.39866127 0.00031086 0.49657642 1.18E-13 0.06431886 8.52E-13 3.91E-07 3.28E-09
rs890293 - - - - - - - - - - -
rs975833 - 0.0999674 5.65E-11 - - 4.30E-09 - - - - 0.02956016
rs9934438 1.86E-24 9.17E-14 0.0001892 0.00092503 1.98E-24 0.02360989 5.38E-33 1.64E-08 1.98E-32 1.07E-09 1.88E-41
a Italics indicated that after adjustment p < 0.05/(85*11) the locus has statistically significant













[20, 21]. Thymidylate synthesis required a lower 5,10-
methylenetetrahydrofolate levels which leading to
misincorporation of uracil into DNA, increasing
chromosome damage frequency. A lower levels of 5-
methyltetrahydrofolate may decrease the methylation
process of homocysteine to methionine which could
lead to hyperhomocysteinemia and DNA hypomethy-
lation. Severe MTHFR enzyme deficiency is the most
common inherited folate metabolism disorder which
leads to hyperhomocysteinemia and homocystinuria
that eventually destroy the central nervous system
Fig. 2 The global frequency distribution of rs1801131. NA, North America; SA, South America
Table 4 The VIP variants in Mongols compared with eleven HapMap groups according to the gene superfamily classification
ASW CEU CHB CHD GIH JPT LWK MEX MKK TSI YRI
rs1045642 rs1229984 rs1229984 rs4148323 rs1540339 rs1229984 rs10264272 rs1695 rs10264272 rs1544410 rs10264272
rs1128503 rs1544410 rs1801272 rs1544410 rs1801272 rs1128503 rs1045642 rs3807375 rs1045642
rs11568820 rs1801272 rs3782905 rs3807375 rs3782905 rs11568820 rs1051266 rs701265 rs1128503
rs1540339 rs3782905 rs776746 rs4124874 rs975833 rs1540339 rs1128503 rs7975232 rs11568820
rs2032582 rs3807375 rs975833 rs4148323 rs1695 rs11568820 rs1229984
rs2066702 rs4148323 rs1801133 rs1540339 rs1540339
rs4124874 rs6277 rs2032582 rs1544410 rs1801133
rs701265 rs698 rs2066702 rs1801133 rs1801252
rs776746 rs7975232 rs2239179 rs1805124 rs1801253
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and vascular system [22]. Several studies revealed
that the C677T and A1298C mutations reduce
MTHFR enzyme activity [20–25]. In Caucasians, the
C677T of TT and CT carriers had 70 % and 35 %
reduced MTHFR enzyme activity, respectively, com-
pared to CC carriers [26]. In Mongolians, CT and
TT carriers had a frequency about 0.39 and 0.09. We
should pay more attention on capecitabine, cisplatin,
pemetrexed, cyanocobalamin and related agents in
the Mongolian. Research of this mutation in other
populations had not been performed. The enzyme
activity reduction extent of different A1298C carriers
had not been researched, but the study would play a
large role in clinical treatment when one medication
cure different patient who carriers different A1298C
genotype.
We randomly selected one of the middle significantly
different variants in Mongols – the non-synonymous
SNP rs1805124 (A1673G-H558R), which is located in
exon 12 of SCN5A [27]. SCN5A encodes the integral
Fig. 3 Rs1540339 frequencies in various global populations. EAsia, East Asia; NA, North America; SA, South America
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membrane protein, voltage-dependent sodium channel
α-subunit. It primarily traffics sodium in human heart
muscle cells [28, 29]. SCN5A can cause fast depolarization
during the upstroke phase of cardiac action potentials,
that is the reason as a molecular antiarrhythmic drug tar-
get [30]. Amounts of Studies reveals SCN5A is associated
with various cardiac diseases including long-QT syndrome
(LQTS), Brugada syndrome (Brs), progressive cardiac con-
duction defect, atrial fibrillation (AF), dilated cardiomyop-
athy, and overlapping syndromes [27–31]. SCN5A-H558R
has been shown to generate moderate electrophysiological
functions that can regulate the phenotypic expression of
cardiac conduction. It is associated with the mechanism of
atrial fibrillation [30, 32] and can modify QTc duration in
people with LQTS [33]. Studies of different genotype
frequencies in various populations related to SCN5A-
H558R function have not yet been performed, but SY
Nikulina.et.al already found that AG genotype of the
H558R (rs1805124) polymorphism of the SCN5A gene is
a genetic predictor of idiopathic disorders of atrioventricu-
lar and intraventricular conduction [34] We can carry out
the prevention and early treatment of these diseases by
gene sequencing.
Among Mongols and others global populations, nu-
merous important genetic variants play critical roles in
drug response and this information should directly ap-
plied to clinical guidelines. For instance rs1540339
(46489G > A), the most significant locus in our data, is
associated with bronchodilator responsiveness [35].
Studies have been performed on the correlation between
Fig. 4 Linkage disequilibrium analysis of the VDR in each of the twelve populations. LD is displayed by standard color schemes with bright red
for very strong LD (LOD > 2, D ′ =1), pink red (LOD > 2, D ′ <1), blue (LOD < 2, D ′ = 1) for intermediate LD, and white (LOD < 2, D′ <1) for no LD
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asthma and rs1540339; however, evaluation of this poly-
morphism in a clinical setting is not yet routine [36, 37].
Beyond the genetic factor, we also determined that
long-term survival in different environments affects gen-
etic adaption. Environmental pressures shape genotype
distributions towards specific functions, particularly in
pharmacogenetic genes. Studies by Janha et al., Sabbagh et
al., and Fuselli et al. directly demonstrated that the differ-
ent genotype frequencies of CYP2C19, NAT2, and
CYP2D6 significantly differed between populations race,
subsistence modes, and dietary habits also play a role in
the evolutionary trajectory [38–40].
Conclusions
Different populations exists different genetic distribute
frequencies. The drug dosage and usage of different geno-
type carriers is difference. Identifying genotype distribu-
tion and VIP variant frequencies in different populations
to determine what medications might be most effective
may provide a theoretical foundation for safe drug admin-
istration and improved curative effects. Besides, we figured
out the minimum allele difference between Mongol and
CDX. We also preliminary supplemented the pharmaco-
genomic data on the Mongol ethnic group and illustrated
the differences between Mongols and other populations,
and finally found Mongol and Chinese populations have
the minimum difference. To the study, the sample size is
relatively small and further investigation using a larger co-
hort of Mongols is needed to verify the generalizability of
our results, and would be help us to establish a more
reasonable and effective individualized treatment plan.
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